Sam have a read of this announcement again. Trial fotmat and end points remain the same as the phase 2d/3 trial. These are still as previously approved by the EMA.
Dosing planned for Q4. Australian sites added. Still placebo, 25 and 50 doses. Expansion trial after the initial 6 months with placebo removed, and 25 and 50 dose size used.
Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-333
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $81.90M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 551601 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 343328 | 1 |
View Market Depth
| Last trade - 09.55am 07/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable